KR102296416B1 - 항-세라마이드 항체 - Google Patents

항-세라마이드 항체 Download PDF

Info

Publication number
KR102296416B1
KR102296416B1 KR1020177006255A KR20177006255A KR102296416B1 KR 102296416 B1 KR102296416 B1 KR 102296416B1 KR 1020177006255 A KR1020177006255 A KR 1020177006255A KR 20177006255 A KR20177006255 A KR 20177006255A KR 102296416 B1 KR102296416 B1 KR 102296416B1
Authority
KR
South Korea
Prior art keywords
ser
antibody
antigen
thr
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177006255A
Other languages
English (en)
Korean (ko)
Other versions
KR20170066327A (ko
Inventor
지미 로톨로
리차드 콜레스닉
Original Assignee
메모리얼 슬로안 케터링 캔서 센터
세라미드 테라퓨틱스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메모리얼 슬로안 케터링 캔서 센터, 세라미드 테라퓨틱스 filed Critical 메모리얼 슬로안 케터링 캔서 센터
Publication of KR20170066327A publication Critical patent/KR20170066327A/ko
Application granted granted Critical
Publication of KR102296416B1 publication Critical patent/KR102296416B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020177006255A 2014-08-07 2015-08-07 항-세라마이드 항체 Active KR102296416B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462034453P 2014-08-07 2014-08-07
US62/034,453 2014-08-07
PCT/US2015/044144 WO2016022883A1 (en) 2014-08-07 2015-08-07 Anti-ceramide antibodies

Publications (2)

Publication Number Publication Date
KR20170066327A KR20170066327A (ko) 2017-06-14
KR102296416B1 true KR102296416B1 (ko) 2021-09-01

Family

ID=55264608

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177006255A Active KR102296416B1 (ko) 2014-08-07 2015-08-07 항-세라마이드 항체

Country Status (12)

Country Link
US (4) US10450385B2 (https=)
EP (2) EP4681733A3 (https=)
JP (1) JP6670297B2 (https=)
KR (1) KR102296416B1 (https=)
CN (1) CN107074949B (https=)
AU (1) AU2015300902B2 (https=)
CA (1) CA2957415C (https=)
IL (1) IL250374B (https=)
MX (1) MX391141B (https=)
RU (1) RU2717651C2 (https=)
SG (1) SG11201700787XA (https=)
WO (1) WO2016022883A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10537633B2 (en) 2016-03-04 2020-01-21 Jn Biosciences Llc Antibodies to TIGIT
CA3048224A1 (en) 2016-12-23 2018-06-28 Bluefin Biomedicine, Inc. Anti-sez6l2 antibodies and antibody drug conjugates
WO2020231629A1 (en) 2019-05-16 2020-11-19 Snake River Bioscience, Inc. Compositions and methods for the treatment of major depressive disorder
JP7623706B2 (ja) * 2019-06-06 2025-01-29 ジャコバイオ ファーマスーティカルズ カンパニー リミテッド Ｃｄ７３に特異的な結合分子と結合分子の使用
US10975169B1 (en) 2019-09-27 2021-04-13 Memorial Sloan Kettering Cancer Center Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibody 2A2
KR102245082B1 (ko) * 2020-02-14 2021-04-26 단국대학교 천안캠퍼스 산학협력단 치주인대전구세포 표면에 특이적으로 결합하는 두 가지 IgG 타입 단일클론항체 LG43, LG73 및 그의 용도
CN115811987A (zh) * 2020-03-18 2023-03-17 纪念斯隆凯特琳癌症中心 抗神经酰胺抗体
MX2022015157A (es) 2020-06-02 2023-01-16 Arcus Biosciences Inc Anticuerpos para tigit.
EP4308231A4 (en) * 2021-03-16 2025-01-29 Memorial Sloan Kettering Cancer Center IMPROVING WOUND HEALING WITH ANTI-CERAMIDE ANTIBODIES
WO2024226646A2 (en) * 2023-04-25 2024-10-31 Memorial Sloan-Kettering Cancer Center Dlk1 -targeting antibodies and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
JPH02128697A (ja) * 1988-11-09 1990-05-17 Hoechst Japan Ltd 抗フコシルセラミドモノクローナル抗体
US7897753B2 (en) 2002-02-20 2011-03-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of XIAP gene expression using short interfering nucleic acid (siNA)
RU2310393C1 (ru) 2006-02-16 2007-11-20 ФГУ Научно-исследовательский институт по изучению лепры Федерального агентства по здравоохранению и социальному развитию Российской Федерации Способ прогнозирования обострений лепрозных невропатий у больных лепрой
JP5924863B2 (ja) * 2007-05-06 2016-05-25 スローン ケタリング インスティテュート フォア キャンサー リサーチ Ｇｉ症候群及び移植片対宿主病を治療及び予防する方法
US9163091B2 (en) 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
WO2009154026A1 (ja) * 2008-06-20 2009-12-23 国立大学法人岡山大学 石灰化小球に対する抗体及びその用途
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
CN102459335B (zh) * 2009-04-17 2015-11-25 伊缪纳斯制药株式会社 特异性结合Aβ寡聚体的抗体及其用途
FR2971250A1 (fr) * 2011-02-07 2012-08-10 Univ Nantes Anticorps anti-gb3 utiles dans le traitement des maladies associees a l'angiogenese
KR101256351B1 (ko) 2011-11-22 2013-04-19 김석진 필터 삽입공을 갖는 카메라 후드
WO2013125654A1 (ja) * 2012-02-21 2013-08-29 東レ株式会社 癌の治療及び／又は予防用医薬組成物
AU2013266069B2 (en) * 2012-05-25 2018-03-15 Sloan Kettering Institute For Cancer Research Methods for treating GI syndrome and graft versus host disease
CN115811987A (zh) * 2020-03-18 2023-03-17 纪念斯隆凯特琳癌症中心 抗神经酰胺抗体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CS Hampe et el., Exp Clin Endocrinol Diabets, 2005, 113(7) 381-387.
Soma Rohathi et al., The Journal of Immunology, 2012, 189(12) 5820-5830.

Also Published As

Publication number Publication date
US20230416409A1 (en) 2023-12-28
EP3177650A4 (en) 2018-01-03
JP2017527544A (ja) 2017-09-21
JP6670297B2 (ja) 2020-03-18
US20250197524A1 (en) 2025-06-19
IL250374B (en) 2021-04-29
AU2015300902A1 (en) 2017-03-02
RU2717651C2 (ru) 2020-03-24
MX391141B (es) 2025-03-21
US20190389970A1 (en) 2019-12-26
CA2957415C (en) 2021-07-13
RU2017105596A (ru) 2018-09-07
CN107074949A (zh) 2017-08-18
EP3177650A1 (en) 2017-06-14
US20170335014A1 (en) 2017-11-23
MX2017001686A (es) 2017-09-01
CA2957415A1 (en) 2016-02-11
NZ728981A (en) 2024-03-22
AU2015300902B2 (en) 2020-05-28
EP4681733A3 (en) 2026-05-06
US10450385B2 (en) 2019-10-22
IL250374A0 (en) 2017-03-30
SG11201700787XA (en) 2017-02-27
RU2017105596A3 (https=) 2019-04-17
BR112017002433A2 (pt) 2017-11-28
EP4681733A2 (en) 2026-01-21
KR20170066327A (ko) 2017-06-14
CN107074949B (zh) 2021-06-15
EP3177650B1 (en) 2025-11-05
WO2016022883A1 (en) 2016-02-11
US11447572B2 (en) 2022-09-20

Similar Documents

Publication Publication Date Title
KR102296416B1 (ko) 항-세라마이드 항체
US20250051451A1 (en) Anti-b7-h3 monoclonal antibody and use thereof in cell therapy
US10273306B2 (en) Antibodies directed against ICOS for treating graft-versus-host disease
KR101537840B1 (ko) 항-인간 ｃｄ52 면역글루불린
US20230203178A1 (en) Chimeric antigen receptor car or car construct targeting bcma and cd19 and application thereof
EA015009B1 (ru) АНТИГЕНСВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ АФФИННОСТЬЮ К СВЯЗЫВАНИЮ С Fc-РЕЦЕПТОРОМ И ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
KR20140006096A (ko) Masp-2 의존적 보체 활성화를 억제하는 조성물
AU2021330879B2 (en) Development of drug therapeutic agent containing adaptor and use thereof
TWI819352B (zh) 包含il-12及抗fap抗體的融合蛋白及其用途
JP2012513761A (ja) 初期の眼内リンパ腫の治療に対する抗ｃｄ２０抗体の使用方法
CA2404340C (en) Methods of blocking tissue destruction by autoreactive t cells
CN117264055A (zh) 一种特异性结合人cd318的vhh抗体或其抗原结合片段及其制备方法和应用
HK40096744A (en) Development of drug therapeutic agent containing adaptor and use thereof
KR20230054451A (ko) 길항작용 cd40 모노클로날 항체를 사용하여 자가면역 질환을 치료하는 방법

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170306

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
A302 Request for accelerated examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200722

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20200722

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200729

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210326

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210601

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210826

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210826

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240722

Start annual number: 4

End annual number: 4